SCHEMBL30452335

SCHEMBL30452335

CCOC(=O)CNC(=O)c1nc(C)cc(CCOCc2ccccc2)c1O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PPID Q08752 1/20 0.43
▸ KMT2A Q03164 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.40
▸ HPGD P15428 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP7 P55210 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ EGLN1 Q9GZT9 2/20 0.39
▸ LTA4H P09960 2/20 0.39
▸ THRA P10827 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257784 1.00 PPID (0.43) PPIDKMT2AL3MBTL1MEN1ALDH1A1
SCHEMBL24257456 0.90 EGLN1 (0.48) EGLN1THRATHRB
Formic Acid SCHEMBL30454433 0.86 EGLN1 (0.45) EGLN1THRATHRB
SCHEMBL30454412 0.82 RNASEH1 (0.40) ALDH1A1HPGDKDM4ETDP1GAA
SCHEMBL24257810 0.82 RNASEH1 (0.40) ALDH1A1HPGDKDM4ETDP1GAA
SCHEMBL24257827 0.81 RNASEH1 (0.47) L3MBTL1ALDH1A1HPGDLMNAKDM4E
SCHEMBL30452343 0.81 RNASEH1 (0.47) L3MBTL1ALDH1A1HPGDLMNAKDM4E
Glycine SCHEMBL30546853 0.80 TDP1 (0.39) KMT2AL3MBTL1MEN1ALDH1A1LMNA
Glycine SCHEMBL29248942 0.77 RNASEH1 (0.37) ALDH1A1HPGDKDM4ETDP1GAA
SCHEMBL30452505 0.76 EGLN1 (0.51) KMT2AMEN1ALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 — — US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 PPID 1401/4885KMT2A 868/4885L3MBTL1 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback